logo
Wrong email address or username
Wrong email address or username
Incorrect verification code
back to top
Search tags: drug-use
Load new posts () and activity
Like Reblog Comment
text 2018-08-13 08:41
Drug Eluting Stents Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis

Worldwide Market Reports added Latest Research Report titled “Drug Eluting Stents Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis”to its Large Report database.

The Global Drug Eluting Stents Market was valued at US$ 5912.9 million in 2016 and is projected to expand at a CAGR of 4.7% during the forecast period (2017-2025), as highlighted in a new report published by Coherent Market Insights. Increase in geriatric population in turn is projected to support growth of drug eluting stents market over the forecast period.
Drug eluting stents are small expandable tubes made of wire that are inserted into the coronary arteries of patients with atherosclerosis. Stent helps to hold the artery open to release a drug that prevents blockage occurring in artery and improves the blood flow. This stent placement are generally carried out in the procedure of coronary angioplasty.
The constantly rise in geriatric population drives the growth of the market as the population is at a high risk of developing arterial diseases. In addition unhealthy dietary habits, sedentary lifestyles and lack of exercise are some of the factors resulting in the increased prevalence of artery diseases. As a result he demand for drug eluting stents is escalating as artery diseases is widely treated by using drug eluting stents. However the decrease in price of this device is enhancing the market growth. Hence this factors are expected to challenge the growth of the market in the forecast period.

Request for Sample Copy of Research Report: https://www.worldwidemarketreports.com/sample/187621

According to the National Institute on Aging the world's geriatric population in 2015 was around 8.5% and it may rise around 17% by 2050. Hence the minimally-invasive techniques of DES placing is expected to enhance the growth of drug eluting stent market.
The drug eluting stents are used for the treatment of artery diseases as a result this application is expected to maintain its dominance throughout the future near. As per the stats published in 2015 by The Heart Foundation, coronary artery disease causes around 380,000 deaths yearly in the U.S. Furthermore, around 720,000 people suffer from heart attacks each year and among these around 205,000 are cases of heart attack. As per the World Health Organization (WHO) it was estimated around 17.7 million people died from cardiovascular diseases (CVDs) in 2015, representing 31% of all global deaths. Among this deaths, an estimated 7.4 million were due to coronary heart disease and 6.7 million were due to stroke. Furthermore around 2% of death is occurred due to rheumatic heart disease.
Get Best Discount on Research Report: https://www.worldwidemarketreports.com/discount/187621

Key takeaways of the market:
• The global drug eluting stents market is expected to expand at a CAGR of 4.7% during the forecast period (2017-2025). Due to rising number of geriatric population and increase in cardiovascular disease cases from around the globe is expected to favor the market of drug eluting stents over the forecast period.
• The North America region in the global drug eluting stents market is expected to show high growth rate followed by Asia Pacific during the forecast period in terms of value
• In terms of product segment, the polymer based coatings type was valued at US$ 5337.4 Mn in 2016 and is expected to reach US$ 8174.3 Mn by 2025 at a CAGR of 4.8%
• The increase in adoption of biodegradable stents is expected to drive the growth of the polymer based coating stents segment.
• In terms of application the coronary artery diseases type was valued at US$ 4117.0 Mn in 2016 and is expected to reach US$ 6334.9 Mn by 2025 at a CAGR of 4.9%
• Drug eluting stents are considered as gold standard for the treatment of coronary artery disease. As a result, this application segment is expected to maintain its dominance in the forecast period.
The major key players of drug eluting stents market are Boston Scientific Corporation, Medtronic, Inc., Abbott Laboratories, Biosensors International Group, Biotronik, Lepu Medical Technology, Terumo Medical Corporation, Cook Medical, Shandong JW Medical Systems, Stentys, Abbott Vascular Inc., AlviMedica Medical Technologies Inc., Amaranth Medical, Inc., HangZhou HuaAn Biotechnology Co.,Ltd, XTENT, Inc., CARDIONOVUM GmbH, Cordis Corporation KYOTO MEDICAL PLANNING Co., Ltd.

**If you have any special requirements, please let us know and we will offer you the report as you want.


About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends. Worldwide Market Research’s well-researched inputs that encompass domains ranging from IT to healthcare enable our prized clients to capitalize upon key growth opportunities and shield against credible threats prevalent in the market in the current scenario and those expected in the near future.

Contact Us:

Mr. Shah

Worldwide Market Reports

1001 4th Ave,

#3200

Seattle, WA 98154,

llU.S

Tel: +1 415 871 0703

Email: sales@worldwidemarketreports.com

Like Reblog Comment
show activity (+)
review 2018-05-31 01:47
Does the Noise in my Head Bother You?
Does the Noise in My Head Bother You? - Steven Tyler

So, I actually finished it.  I know, I'm a glutton for punishment.  I just wanted to count it toward my reading goal since I had already read half of it.  I gave it 2 stars instead of 1 because I actually finished it.  If I hadn't been able to finish it and it ended up in the trash, or the street (close) I would have given it only one star.  

 

---------------------------

 

Terrible.  So I knew they were crazy, did a lot of drugs and I assumed a lot of crazy sex but I didn't not expect that to be pretty much the whole book.  I did enjoy the first few chapters about his childhood.  I looked up the people and songs he mentioned and listened to some of them online.  Then, he starts talking about doing drugs and sex and fighting with his band mates and he sounded like a whiny child.  He truly only thinks about himself and justifies his actions while at the same time acknowledging he was wrong and sorry.  This book was a rambling mess and unfortunately there are things you can't unknow.

 

Omg, so I was reading reviews other people wrote and this one is so funny because it is exactly what I was thinking.  Only this person writes it like a letter to Steven Tyler.  

Review by Jennifer

Like Reblog Comment
show activity (+)
text 2018-05-29 21:00
Reading progress update: I've read 170 out of 390 pages.
Does the Noise in My Head Bother You? - Steven Tyler

Terrible.... complete waste of time.  

 

I was hoping for some cool music stuff but I only semi-enjoyed the first chapter or two about his childhood.  I finally looked up the audio book and let it play while I did other things.  It is not really worth any time and some of the stuff I've heard I'll never be able to unknow.  I'll probably just flip through the rest looking for anything worth my time.  

Like Reblog Comment
text 2018-05-28 13:31
Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

 

Overview:

Acute Lymphoblastic Leukemia is a type of cancer which affects white blood cells. It is also called as Acute lymphocytic leukemia. IALL progresses rapidly without treatment. Acute lymphoblastic leukemia (ALL) is a malignant (clonal) disease of the bone marrow in which early lymphoid precursors proliferate and replace the normal hematopoietic cells of the marrow. Symptoms of ALL includes fever, anemia, bleeding, blood clots, bone pain, rashes on skin, Palpable lymphadenopathy etc.

ALL is diagnosed by coagulation studies, blood tests, X-Ray, CT-Scan, ECG, MRI, bone marrow aspiration and biopsy etc. Treatment of ALL includes induction chemotherapy, consolidation chemotherapy, Stem cell transplantation and others.

 

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/acute-lymphoblastic-leukemia-disease-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx

 

Segmentation:

By Trial Phase, Acute Lymphoblastic Leukemia pipeline drugs are segmented as:

  • Preclinical Trials
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4

By Company, Acute Lymphoblastic Leukemia pipeline drugs are segmented as:

  • Novartis
  • Pfizer
  • Ariad Pharmaceuticals
  • Juno Therapeutics
  • Janssen
  • Amgen
  • (Erytech Pharma
  • Bristol-Myers Squibb
  • Others

By Drugs, Acute Lymphoblastic Leukemia pipeline drugs are segmented as:

  • Blinatumomab
  • Carfilzomib
  • calaspargasepegol
  • Dasatinib
  • Ibrutinib
  • Inotuzumabozogamicin
  • Ofatumumab
  • Ponatinib
  • Others

By Route of Administration, Acute Lymphoblastic Leukemia pipeline drugs are segmented as:

  • Oral
  • Parenteral

 

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/acute-lymphoblastic-leukemia-disease-pipeline-drugs-assessment/#ulp-c654SbFYO64MsOhu

 

 

Space Analysis:

  • In October 2015, Seattle Genetics, Inc.initiated randomized phase II clinical trial of denintuzumabmafodotin (SGN-CD19A) in combination with second-line salvage regimen of rituximab (Rituxan), ifosfamide, carboplatin and etoposide (RICE), for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
  • In September 2017, Kiadis pharma’s ATR101 was granted Regenerative Medicine Advanced Therapy (RMAT) designation by U.S.FDA and in April 2017, Kiadis pharma received regulatory approval from the national authority in Belgium to start pivotal Phase III trial with ATIR101™ and from the national authority in Germany to start the Phase I/II trial with ATIR201 for patients suffering from blood cancers

 

Report Description:

Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Acute Lymphoblastic Leukemia treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Acute Lymphoblastic Leukemia disease pipeline drugs development. This report studies the dynamics of the Acute Lymphoblastic Leukemia Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Acute Lymphoblastic Leukemia disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

 

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/acute-lymphoblastic-leukemia-disease-pipeline-drugs-assessment/#ulp-14mlyhjMGhVjZqa3

 

Key Features of the Report:

  • Provides the information related to universities and research institutes working in the therapeutics development
  • Report comprehensively covers the all active and discontinued studies
  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
  • Presents the prominent targets for drug development in each stage of clinical trial
  • Provides the in-depth analysis on the each drug candidates in the clinical trial phases

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/acute-lymphoblastic-leukemia-disease-pipeline-drugs-assessment/

About Precision Business Insights

 

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

 

Contact to Precision Business Insights,

 

Kemp House,

152 – 160 City Road,

London EC1V 2NX

 

Email: sales@precisionbusinessinsights.com

 

Toll Free (US): +1-866-598-1553

Website @ https://www.precisionbusinessinsights.com

 

More posts
Your Dashboard view:
Need help?